Japanese cedar pollinosis in children
Conditions
Interventions
Pranlukast dry syrup are orally administered to 15 subjects at twice daily two months. Japanese cedar pollen exposure mid-Feb. in OHIO Chamber.
Placebo dry syrup are orally administered to 15 subject
Sponsors
Nippon Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Multiple antigen simultaneous test score against Japanese cedar pollen over class 2 in the past. 2)Have experience with cedar pollen exposure in OHIO Chamber in the past,patients with nasal symptoms with nasal congestion. 3)Patients who were judged to be suitable for patients enrollment by doctor in screening visit or medical examination results. 4)Written informed consent is required.
Exclusion criteria
Exclusion criteria: 1)Some patients with mucosal lesion of the nose and eyes. 2)Patients who received steroid injections within 6 months. 3)Subjects with deformity of the nose polyp. 4)Subjects with systemic diseases(asthma or tuberculosis). 5)Patients with past history of anaphylaxis. 6)Patients who have the hypersensitivity to study drug. 7)Patients who have received immunotherapy. 8)Patients who were judged to be unsuitable for patients enrollment by doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nasal symptoms score | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)No of sneezing 2)Nasal secretion volume 3)Occurrence time of the first nasal symptoms 4)Consumption of rescue medicine 5)Eosinophil cationic protein | — |
Countries
Japan
Contacts
Public ContactSatoko Shimizu
Tokyo Reserch Center of Clinical Pharmacology co.,ltd. CRC Section ,Clinical Trial Operations Support Dept.
Outcome results
None listed